-Bloomberg
Candel Therapeutics Announces Late-breaking Oral Presentation At SITC Annual Meeting With Data On CAN-2409 In Combination With Nivolumab In A Phase 1 Mechanistic Clinical Trial In Patients With High-grade Glioma
Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standard of care
Systemic immune activation was observed in peripheral
